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Rats made dependent on heroin and morphine exhibit both qualitative and quantitative differences in the characteristics 
of radioligand binding to p-opioid receptors in the central nervous system. In brain membranes prepared from control 
animals, PHldihydromorphine (DHM) binding was best described by a two-site model, while in morphine-dependent 
rats, PH]DHM binding was best described by a single-site model. In contrast, PH]DHM binding to membranes from 
heroin-dependent animals was best described by a two-site model, with an increased density of the high-affinity, and no 
change in the low-affinity population compared to controls. Furthermore, both the number of binding sites for 
PH]DAGO (a hgand that selectively labels a population of high-affinity p-opiate receptors) and the sensitivity of 
[‘H]DHM to sodium ions was increased in heroin; but not in morphine-dependent rats. These studies demonstrate that 
opiate receptors are differentially regulated in heroin- and morphine-dependent animals. Such neurochemical changes 
in p-opiate receptors may underlie differences in the behavioral and pharmacological profiles of heroin and morphine 
reported in man. 
Diacctylmorphine; Opiate dependence; Na+; Morphine; Tyr-D-Ala-Gly-Mephe-Gly-ol 
1. INTRODUCTION 
Several lines of evidence suggest that the 
development of tolerance and dependence to 
opiates involves alterations in recognition sites for 
these compounds, levels of endogenous opioid 
compounds and effector phenomena [l-S]. While 
two of the most widely abused opiates, morphine 
and heroin (3,6_diacetylmorphine) [9- 1 l] are 
structurally similar, the pharmacological actions 
of heroin are generally attributed to the 
metabolites 6-acetylmorphine and morphine 
[ 12,131. Nonetheless, studies with both opiate- 
naive subjects and former heroin addicts have 
noted significant differences in the phar- 
macological effects of heroin and morphine. For 
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example, heroin had a more rapid onset of action, 
a shorter abstinence syndrome and was the prefer- 
red drug in heroin addicts [9,11,14,15]. While the 
metabolism of heroin to morphine and 
6-acetylmorphine can be invoked to explain some, 
but not all of these differences, recent studies 
strongly suggest that the pharmacological effects 
of heroin are not dependent on its conversion to 
active metabolites [ 14,151. Previous attempts to 
associate morphine dependence in experimental 
animals with alterations in opiate receptors have 
yielded inconsistent findings [ 16-221, while a 
direct comparison of the effects of heroin and 
morphine dependence on opioid receptors has not 
been examined. 
Since heroin contains two functional groups (the 
3- and 6-acetyl moieties) that have the potential to 
covalently acylate opioid receptors [23,24], we 
compared radioligand binding to p-opiate recep- 
tors in heroin- and morphine-dependent rats to 
determine whether a differential effect of these 
compounds on opiate receptors may be responsible 
for the pharmacological differences observed after 
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administration of these opiates [9,11,14,15]. We 
now report both qualitative and quantitative 
changes in the binding of radioligands to p-opioid 
receptors in the central nervous system of heroin- 
and morphine-dependent rats. These findings may 
provide the neurochemical bases for some of the 
differences reported in the pharmacological ac- 
tions of heroin and morphine. 
2. MATERIALS AND METHODS 
Male Sprague-Dawley rats (Taconic Farms, Germantown, 
NY) weighing 175-200 g were implanted with heroin, morphine 
or placebo (control) pellets in the dorsal subcutaneous space. 
Pellets were implanted under light ether anesthesia. 72 h later, 
animals were killed by decapitation, their brains rapidly re- 
moved and the cerebella discarded. Tissues were homogenized 
(Brinkman polytron, 15 s, setting 6-7) in 20 vols of potassium 
phosphate buffer (20 mM, pH 7.4) and the homogenates cen- 
trifuged for 15 min at 27000 x g. The homogenates were 
resuspended in an equal volume of buffer, recentrifuged twice 
more, and resuspended in 40 vols of buffer. This washing pro- 
cedure was sufficient to remove heroin or morphine from brains 
that were initially resuspended in 40 vols of buffer containing 
100 nM of either drug (not shown). [3H]Dihydromorphine 
(DHM) or [3H]Tyr-D-Ala-Gly-Mephe-Gly-ol (DAGO) binding 
to brain membranes was assayed in a total assay volume of 1 ml 
consisting of 0.5 ml of membrane suspension (0.5-0.8 mg pro- 
tein), 0.1 ml of radioligand (ten concentrations ranging from 
0.15-14.0 nM) and 0.4 ml of buffer. In some experiments, 
0. I ml of buffer was replaced with 0. I ml of NaCl (to yield final 
Na+ concentrations of LO-100 mM). Nonspecific binding was 
determined in the presence of 10/M naloxone HCI. Mem- 
branes were incubated for 30 min at 25°C and the binding ter- 
minated by rapid filtration through Whatman OF/B filters 
using a Brandel M-24R cell Harvester (Brandel Instruments, 
Gaithersburg, MD), followed by two 5 ml washes with ice-cold 
buffer. Protein was determined according to the Miller 
modification [25] of the Lowry technique [26]. 
Pellets were made by Innovative Research of America 
(Gaithersburg, MD). The binder consisted of dicalcium 
phosphate, tricalcium phosphate, stearic acid, cholesterol, 
methyl cellulose and lactose. Placebo pellets contained binder 
only. [‘HIDHM (spec. act. 65 Ci/mmol) and [‘HIDAGO (spec. 
act. 45 Ci/mmol) were obtained from Amersham, Arlington 
Heights, IL. Naloxone HCI was obtained from Endo Labs, 
Wilmington, DE. All other chemicals were obtained from stan- 
dard commercial sources. 
3. RESULTS 
Initial attempts to formulate heroin and mor- 
phine pellets in an identical manner resulted in an 
unacceptably high rate of mortality in the former 
group (>80%). Double coating of the heroin 
pellets reduced lethality to ~5%. In some ex- 
periments, naloxone HCI was administered 
Ii I 
C M 
i 
I 
L 
C 
* 
120. 
1 EO- I- 40- 
H 
II 
M C H 
Fig. 1. [-‘H]DHM binding in morphine- and heroin-dependent 
rats. [‘H]DHM binding to rat brain membranes was measured 
in control (open bars) and dependent rats (closed bars). The 
ligand concentrations used were 0.32 nM (left panel) and 
13.2 nM (right panel). C, placebo-implanted rats; M, 
morphine-implanted rats; H, heroin-implanted rats. The results 
are presented as the mean * SE of 6-8 experiments. 
* Significantly different from control, p < 0.05, Student’s 
t-test. 
(2 mg/kg, i.p.) to rats that had been implanted 
with either morphine, heroin or placebo pellets. 
Naloxone produced a similar abstinence syndrome 
[27,28] in animals implanted with either heroin or 
morphine consisting of: wet dog shakes, teeth 
chattering, irritability, vocalization and diarrhea. 
Table 1 
[‘HIDHM binding in heroin- and morphine-dependent rats 
Treatment Model & B max 
WU (fmol/mg protein) 
Placebo 2 site 0.6 f 0.2 44.8 + 8.5 
27.5 f 13.1 280.6 i 88.8 
Morphine 1 site 1.7 ?I 0.2 146.6 f 8.0 
Heroin 2 site 0.7 + 0.1 79.7 + 6.8” 
19.5 + 10.1 147.8 f 31.1 
a Significantly different from control, p < 0.05, unpaired 
Student’s t-test 
[‘HIDHM binding to brain membranes prepared from placebo- 
, morphine- or heroin-dependent rats was assayed as described 
in section 2. Data were analyzed by nonlinear regression 
(BMDPAR, University of California, 1977) using the equation: 
where B = total ligand bound; BN = maximum binding capacity 
of site N with an apparent dissociation constant, KN; L = free 
ligand concentration. The binding model that best fitted the 
data was determined using an F-test @ < 0.05). The results are 
the X + SE of 6-8 experiments. For each experimental group 
of rats, a control group was examined concomittantly 
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Fig.2. Scatchard plots of [jH]DHM binding to brain 
membranes from morphine- and heroin-dependent rats. 
[3H]DHM binding to brain membranes from (A) morphine- 
dependent and (B) heroin-dependent rats. (0) Placebo 
implanted rats; (m) morphine (upper panel) and heroin (lower 
panel)-implanted rats; f?, radioligand bound (fmol/mg 
protein); F, free radioligand concentration (fM). Each data 
point is the mean of 6-8 experiments. The Kd and B,,, values 
of binding are presented in table, 1. 
In pilot experiments (fig. l), a statistically signifi- 
cant increase in [3H]DHM binding was observed in 
brain membranes prepared from heroin-implanted 
animals compared to controls when these tissues 
were assayed at low (0.32 nM) radioligand concen- 
trations. In contrast, a significant reduction in 
[3H]DHM binding (13 nM) was observed in mem- 
branes from morphine-implanted rats compared to 
controls. Analysis of [3H]DHM binding to control 
membranes demonstrated that these data were best 
fitted to a two-site model (table 1, fig.2). This 
observation is in agreement with other reports 
[29,30] that have described high- and low-affinity 
[3H]DHM binding sites. In contrast, [3H]DHM 
binding to membranes from morphine-dependent 
rats was best described by a single population of 
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Fig.3. Scatchard plots of [‘HIDAGO binding to brain 
membranes from heroin- and morphine-dependent rats. 
[‘HIDAGO binding was measured in placebo-implanted (o), 
morphine-implanted (0) and heroin-implanted (A) rats. The 
Kd and B,,, values are: 1.3 k 0.2 nM, 177.5 + 13.5 fmol/mg 
protein; 1.3 f 0.3 nM, 171.6 k 10.1 fmol/mg protein; and 
1.1 f 0.1 nM, 218.6 + 6.9* fmol/mg protein; in control-, 
morphine- and heroin-implanted animals, respectively. The 
data are the X f SE of 6-7 experiments. * Significantly 
different from control, p < 0.01, Student’s r-test. [-‘HIDAGO 
binding was not significantly different from control in 
morphine-dependent rats. 
sites with a lower apparent affinity (Kd) and a 
higher maximum binding site density (Bmax) than 
the high affinity opiate receptors found in mem- 
branes from control rats (fig.2a; table 1). The 
binding of [3H]DHM to opiate receptors in heroin- 
dependent animals was qualitatively similar to that 
observed in control rats. However, a significantly 
higher density (79%; p < 0.05) of high-affinity bin- 
ding sites was observed in membranes from heroin- 
dependent animals, with no change in Kd com- 
pared to control tissues (table 1, fig.2B). 
Consistent with previous findings [30-351, 
[3H]DAG0 was found to bind with high affinity to 
a single population of p-opiate receptors in mem- 
branes from control animals. While t3H]DAG0 
binding was not significantly altered in tissues 
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Fig.4. Inhibition of [‘HIDHM binding to brain membranes by 
Na+ in heroin- and morphine-dependent rats. The ability of 
Na+ to inhibit [‘HIDHM binding was studied in control (o), 
heroin-dependent (A) and morphine-dependent (B) rats. 
Maximum inhibition (50%) of [‘H]DHM binding by Na+ in 
control and dependent rats was obtained at a concentration of 
100 mM. The ICse values (mM) for maximal inhibition of 
[‘H]DHM binding by Na’ were for control 49.9 t 4.7, for 
morphine-dependent rats 39.8 k 7.3, and for heroin-dependent 
rats 23.5 k 6.4 (significantly different from control, p < 0.05, 
unpaired Student’s f-test). For each experiment the ICSO value 
was calculated by probit analysis. The I&O values are presented 
as the mean + SE of 6-8 experiments. Each data point is the 
mean of 668 experiments with the error bars omitted for clarity. 
from morphine-dependent rats, a significant in- 
crease (23%) in the B,,, of [3H]DAG0 (fig.3) was 
found in membranes from heroin-dependent 
animals. 
The effect of Na’ on t3H]DHM binding was ex- 
amined in membranes from placebo-, morphine- 
and heroin-implanted rats. Under the conditions 
employed in this study, [3H]DHM binding was in- 
hibited to a maximum of -50% in all groups at 
100 mM Na+. However, Na+ was almost twice as 
potent an inhibitor of [3H]DHM binding in tissues 
from heroin-treated animals (I&, = 23.5 k 
6.4 mM) than in either the placebo (ICXI = 49.9 f 
4.7 mM) or morphine (IC50 = 39.8 f 7.3 mM)- 
treated groups (fig.4). 
4. DISCUSSION 
Despite evidence that suggests that the phar- 
macological effects of heroin are produced 
through its deacylated metabolites morphine and 
6-acetylmorphine [ 12,131, the findings described 
here demonstrate that heroin and morphine 
dependence differentially affect radioligand bin- 
ding to opiate receptors in the central nervous 
system. As previously reported [27,29], [3H]DHM 
was found to bind to two populations of opiate 
receptors in membranes prepared from control 
rats. In morphine-dependent rats, only a single 
population of opiate receptors was detected with 
[3H]DHM that had Kd and B,,, values approx. 3 
times greater than the high-affinity opiate recep- 
tors present in control tissues. While the effect of 
morphine dependence on opiate receptor dynamics 
has been controversial [16-221, our finding that p- 
opiate receptors can be regulated by prolonged ex- 
posure to heroin and morphine is consistent with 
the hypothesis that these sites may mediate 
dependence and tolerance to opiates [22,27]. 
Moreover, a qualitatively different effect on p- 
opiate receptor dynamics was observed in tissues 
prepared from heroin- and morphine-dependent 
animals (table 1 and figs 2,3). The observation that 
an increased number of binding sites for 
[3H]DAG0 was found in heroin-, but not 
morphine-dependent animals (fig.3) is consistent 
with the increase in high-affinity binding sites for 
[3H]DHM found in these animals, since 
[3H]DAG0 has been reported to selectively label a 
population of high-affinity p-opiate receptors 
[30-321. Further, the increased potency of Na+ to 
inhibit [3H]DHM binding in membranes from 
heroin-treated rats underscores the differential ef- 
fects of heroin and morphine dependence on 
opiate receptors, and is consistent with previous 
findings suggesting that post-receptor phenomena 
such as coupling to second messenger systems is 
altered by opiate dependence [1,6]. 
The differences observed in radioligand binding 
to tissues from heroin- and morphine-dependent 
rats may not be attributable to either differences in 
the brain concentrations of these drugs or residual 
amounts of these drugs in membranes since: (i) the 
severity of naloxone-precipitated withdrawal was 
similar in morphine- and heroin-dependent rats 
and (ii) the washing procedure employed was suffi- 
cient to remove exogenously added opiates (see 
section 2). The present findings strongly suggest 
that the metabolic conversion of heroin to mor- 
phine and 6-acetylmorphine may not account for 
either all the pharmacological actions of heroin or 
the differential regulation of opiate receptors in 
morphine- and heroin-dependent rats. However, 
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the presence of potential acylating groups on 
heroin (the 3- and 6-acetyl moieties) that may 
covalently modify opiate receptors might account 
for both the differential regulation of opiate recep- 
tors reported here and the differences in phar- 
macological profile observed between morphine 
and heroin [4,5,9,11]. ,&Flunaltrexamine and ,0- 
chloroflunaltrexamine [23,24] are examples of 
such G-substituted morphinans containing 
acylating moieties that covalently attach to opiate 
receptors. These findings [24] suggest that p-opiate 
receptors possess a reactive bionucleophile that can 
undergo electrophilic attack by G-substituted 
acylating groups on the morphinan ring. While the 
3-acetyl group on the heroin molecule rapidly 
undergoes hydrolysis to yield the biologically ac- 
tive 6-acetylmorphine both in vivo and in vitro 
[lo], the Cs-acetyl group of heroin f&fills the 
criterion of a reactive 6-acetylating morphinan 
capable of electrophilic attack at a reactive 
bionucleophile in the active site of the p-opiate 
receptor. Acylation of p-opiate receptors need not 
lead to a blockade of agonist-receptor interactions, 
but may be capable of effecting the changes 
described here. The hypothesis that heroin 
chemically alters opiate receptors in dependent 
animals is currently under investigation. 
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